Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$88.74 USD
+4.62 (5.49%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.74 USD
+4.62 (5.49%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $88.71 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) led by continued strength across the Screening and Precision Oncology businesses.
Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves
by Zacks Equity Research
Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.
Masimo's (MASI) New FDA Approval to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
Penumbra (PEN) Launches New Technology for Blood Clot Removal
by Zacks Equity Research
Penumbra (PEN) launches Lightning Bolt 7, a new technology that can remove blood clots faster and more efficiently with modulated aspiration.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Revvity (RVTY) Launches New System for Autoimmune Diagnostics
by Zacks Equity Research
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.
HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
Thermo Fisher's (TMO) Unveils Orbitrap Astral Spectrometer
by Zacks Equity Research
Thermo Fisher's (TMO) OrbitrapTM AstralTM mass spectrometer enables accurate and exact quantification in proteomics laboratories.
Hologic (HOLX) Stock Up 5.6% YTD: Will the Rally Continue?
by Zacks Equity Research
The higher capital equipment revenues, procedural volumes return and an acceleration from the new business lines poise Hologic (HOLX) for future growth.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.
Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Illumina's (ILMN) New AI Tool to Predict Genomics Disease
by Zacks Equity Research
Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Haemonetics (HAE) Hospital Arm Grows, Plasma Volume Improves
by Zacks Equity Research
Within Haemonetics (HAE) Vascular Closure, growth is led by the opening of new accounts and increasing penetration to gain share in the top U.S. EP hospitals.
Charles River (CRL) to Build RightSource Lab With New Pact
by Zacks Equity Research
Charles River (CRL) will establish a CGMP testing lab at Wheeler's factory through latest partnership.
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
by Zacks Equity Research
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical
by Zacks Equity Research
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), led by the impressive performance of Plasma and Hospital businesses.
Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
Stryker's (SYK) Q Guidance Successful in First Surgery
by Zacks Equity Research
Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.